Literature DB >> 16234545

Gallbladder cancer, a different disease that needs individual trials.

Jorge Gallardo, Betzabé Rubio, Luis Villanueva, Olga Barajas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16234545     DOI： 10.1200/JCO.2005.02.7524

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

1.  Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.

Authors:  Sam J Lubner; Michelle R Mahoney; Jill L Kolesar; Noelle K Loconte; George P Kim; Henry C Pitot; Philip A Philip; Joel Picus; Wei-Peng Yong; Lisa Horvath; Guy Van Hazel; Charles E Erlichman; Kyle D Holen
Journal:  J Clin Oncol       Date:  2010-06-07       Impact factor: 44.544

2.  A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status.

Authors:  Hiroshi Yoshida; Kazuaki Shimada; Tomoo Kosuge; Nobuyoshi Hiraoka
Journal:  Virchows Arch       Date:  2016-01-13       Impact factor: 4.064

Review 3.  Current management of gallbladder carcinoma.

Authors:  Andrew X Zhu; Theodore S Hong; Aram F Hezel; David A Kooby
Journal:  Oncologist       Date:  2010-02-10

4.  Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report.

Authors:  Kabir Mody; Edward Strauss; Robert Lincer; Richard C Frank
Journal:  BMC Cancer       Date:  2010-10-20       Impact factor: 4.430

5.  Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma.

Authors:  Sakti Chakrabarti; Tyler J Zemla; Daniel H Ahn; Fang-Shu Ou; Briant Fruth; Mitesh J Borad; Mindy L Hartgers; Jaclynn Wessling; Rachel L Walkes; Steven R Alberts; Robert R McWilliams; Minetta C Liu; Lori M Durgin; Tanios S Bekaii-Saab; Amit Mahipal
Journal:  Oncologist       Date:  2019-12-11

Review 6.  Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review.

Authors:  Joon Oh Park; Do-Youn Oh; Chiun Hsu; Jen-Shi Chen; Li-Tzong Chen; Mauro Orlando; Jong Seok Kim; Ho Yeong Lim
Journal:  Cancer Res Treat       Date:  2015-05-18       Impact factor: 4.679

7.  Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials.

Authors:  A D Wagner; P Buechner-Steudel; M Moehler; H Schmalenberg; R Behrens; J Fahlke; A Wein; S Behl; O Kuss; G Kleber; W E Fleig
Journal:  Br J Cancer       Date:  2009-11-10       Impact factor: 7.640

8.  Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study.

Authors:  T André; J M Reyes-Vidal; L Fartoux; P Ross; M Leslie; O Rosmorduc; M R Clemens; C Louvet; N Perez; F Mehmud; W Scheithauer
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.